Indian Court Blocks Sinopharm Weiqida Over Centrient's Amoxicillin
India’s High Court in Delhi has issued an injunction restraining China’s Sinopharm Weiqida from exporting, importing and selling its amoxicillin trihydrate in India, as it infringes Centrient’s patent. Sinopharm Weiqida has also been found guilty of contempt of court for failing to follow a preliminary injunction order that was issued in April 2017.
You may also be interested in...
Netherlands-based Centrient Pharmaceuticals, a global leader in producing “sustainable” enzymatic antibiotics, next-generation statins and antifungals, has filed a second lawsuit against Indian company Dalas Biotech accusing it of patent infringement.
Centrient Pharmaceuticals, which makes “sustainable antibiotics,” has filed an Indian lawsuit in the Delhi High Court against Dalas Biotech accusing the Indian company of patent infringement over its amoxicillin trihydrate API.
Changing its name to Centrient Pharmaceuticals marks the next phase in DSM Sinochem Pharmaceuticals’ “strategic evolution” as a global generics pharmaceutical company, in a move resulting from its recent takeover by Bain Capital.